摘要
目的比较小剂量布地奈德吸入联合扎鲁司特与大剂量布地奈德吸入治疗轻中度支气管哮喘的疗效。方法加例18-70岁轻中度哮喘患者随机分为扎鲁司特组（20例，布地奈德干粉600μg／d吸入；扎鲁司特20mg口眼，每天2次）和对照组（20例，布地奈德干粉1200μg／d吸入），持续治疗6周。于治疗前和治疗6周后进行临床评估和肺功能检查。结果扎鲁司特组与对照组治疗后哮喘发作天数百分数及日间和夜间哮喘症状评分较治疗前显著降低，沙丁胺醇用量较治疗前显著减少，肺功能指标较治疗前显著改善，扎鲁司特组与对照组之间疗效比较，差异无统计学意义。结论小剂量布地奈德吸入联合扎鲁司特与大剂量布地奈德吸入在改善哮喘症状上差异无统计学意义。
Objective To compare zafirlukast plus low - dose inhaled budesonide with high - dose inhaled budesanide on control of mild to moderate asthma. Methods Forty patients aged 18 -70 years with mild to moderate asthma were randomly divided into zafirlukast group （20 cases,zafirlukast 20 rag, twice a day budesunide 600 μg/d by Turbuhaler） and control group（20 cases ,budesonide 1200 μg/d by Turbuhaler ）. Clinical effects and pulmonary function were evaluated before starting therapy, and after 6 weeks therapy. Result After 6 weeks therapy, the percentage of asthma exacerbation days and asthma symptom scores in both groups were significantly decreased than before starting therapy and both groups had significantly greater improvements in 132 agonist use and lung function after 6 weeks therapy, there was no significant difference in clinical effect between two groups. Conclusion The addition of zafirlukast with low - dose inhaled budesonide is equivalent to high - dose inhaled budesonide in the therapy of patients with mild to moderate asthma.
出处
《中国医师进修杂志（内科版）》
2006年第11期44-45,共2页
Chinese Journal of Postgraduates of Medicine
